Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05003076 · ClinicalTrials.gov registry record · Early Phase 1
Brain Function and EEG
A Early Phase 1 study, sponsored by University of Chicago.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 40
- Enrollment target
NCT05003076 is a Early Phase 1 study that has completed, run by University of Chicago. The registered enrollment target is 40 participants.
The verdict
NCT05003076, a Early Phase 1 study, has completed, sponsored by University of Chicago.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
In this project, we will examine effects of MA on reward function using electroencephalograms (EEG), which will complement our ongoing study with MA and fMRI. We will determine how MA alters reward-related neural activity and how this is related to its subjective rewarding effects. The effects of MA on reward function will be examined using both reward-task-related activation and resting state activity. We will examine the effects of MA on ratings of drug liking and euphoria, as well as on EEG measures sensitivity to reward. Healthy young adults will undergo three EEG sessions with placebo and MA (10 and 20 mg), while performing the Monetary Incentive Delay task and the Stop Task, as a measure of inhibition. We will examine correlations between the neural responses and subjective responses to MA. Our central hypotheses are 1) that MA will increase feelings of alertness and well-being, and 2) that MA will increase neural responses to anticipation and receipt of reward, and 3) that the effects of MA on mood will be correlated with its effects on neural responses to reward.
Interventions
- DRUG Placebo
- DRUG Methamphetamine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2021-07-01 |
| Est. Completion | 2023-04-01 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05003076
The ClinicalTrials.gov registry entry for NCT05003076 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05003076 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05003076 about?
NCT05003076 is a clinical study titled "Brain Function and EEG". In this project, we will examine effects of MA on reward function using electroencephalograms (EEG), which will complement our ongoing study with MA and fMRI. We will determine how MA alters reward-related neural activity and how this is related to its subjective rewarding effects. The effects of MA...
What is the current status of trial NCT05003076?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 40 participants. The study started on 2021-07-01. Estimated completion is 2023-04-01.
What interventions are being tested in trial NCT05003076?
The interventions under investigation include: Placebo (DRUG), Methamphetamine (DRUG).
Who is sponsoring clinical trial NCT05003076?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.